Internal Medicine, Cardiovascular Disease · New Castle, PA
NPI
1861457897
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2602 Wilmington Rd, Suite 200
New Castle, PA, 16105
Phone (724) 657-3204
Groups this clinician bills Medicare through
Medicare paid, 2024
$201K
3,059 services
Medicare patients, 2024
698
Average age 76
Drug cost, 2024
$3.8M
21,128 prescriptions
Company payments, 2025
$2,897
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul E Wawrzynski II was code J2785 (injection, regadenoson, 0.1 mg), 484 times for 121 patients. In total Paul E Wawrzynski II billed 3,059 services in 30 codes, and Medicare paid $201K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2785 Injection, regadenoson, 0.1 mg | Office | 484 | 121 | $4.99 | $2,417 |
| 93306 Echocardiography (TTE/TEE) | Office | 387 | 361 | $134.91 | $52K |
| 93000 Electrocardiogram | Office | 363 | 277 | $9.59 | $3,480 |
| 99214 Office E&M - Established | Office | 271 | 204 | $87.52 | $24K |
| 99213 Office E&M - Established | Office | 176 | 150 | $63.66 | $11K |
| 93015 Electrocardiogram | Office | 173 | 166 | $47.14 | $8,156 |
| 99232 Hospital E&M - Subsequent | Facility | 169 | 57 | $59.50 | $10K |
| A9500 Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 157 | 152 | $59.64 | $9,363 |
| 78452 Myocardial Perfusion Scan | Office | 153 | 152 | $305.00 | $47K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 147 | 136 | $12.41 | $1,824 |
| 93010 Electrocardiogram | Facility | 139 | 64 | $6.12 | $851 |
| 99204 Office E&M - New | Office | 76 | 76 | $107.07 | $8,137 |
| 93306 Echocardiography (TTE/TEE) | Facility | 71 | 69 | $51.49 | $3,656 |
| 99222 Hospital E&M - Initial | Facility | 53 | 46 | $97.50 | $5,167 |
| 99203 Office E&M - New | Office | 38 | 38 | $81.72 | $3,105 |
By year: 2022 $236K for 3,246 services; 2023 $229K for 2,995 services; 2024 $201K for 3,059 services.
Medicare prescription drug claims, 2024
In 2024, the drug Paul E Wawrzynski II prescribed most often to Medicare patients was Eliquis (Apixaban), with 1,532 prescriptions and refills. In total Paul E Wawrzynski II wrote 21,128 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 1,532 | 2,303 | 291 | $1.3M |
| Metoprolol Succinate Generic | 1,531 | 3,038 | 347 | $18K |
| Atorvastatin Calcium Generic | 1,342 | 3,178 | 322 | $13K |
| Carvedilol Generic | 1,296 | 2,539 | 288 | $11K |
| Metoprolol Tartrate Generic | 994 | 2,024 | 239 | $6,855 |
| Lisinopril Generic | 974 | 2,146 | 249 | $6,375 |
| Amlodipine Besylate Generic | 965 | 2,067 | 242 | $5,087 |
| Spironolactone Generic | 850 | 1,536 | 209 | $4,787 |
| Chlorthalidone Generic | 816 | 1,535 | 212 | $9,098 |
| Rosuvastatin Calcium Generic | 751 | 1,652 | 191 | $9,657 |
| Ramipril Generic | 593 | 1,197 | 135 | $3,572 |
| Xarelto Rivaroxaban | 591 | 837 | 96 | $449K |
| Clopidogrel Clopidogrel Bisulfate | 585 | 1,223 | 146 | $5,728 |
| Furosemide Generic | 485 | 876 | 146 | $1,927 |
| Entresto Sacubitril/Valsartan | 471 | 677 | 92 | $430K |
Brand drugs: 4,158 claims; generic drugs: 16,970 claims; opioid claims: 74.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul E Wawrzynski II $2,897 ($2,897 in general payments such as food, travel and fees) from 23 companies. The largest payer was Amgen Inc. with $350.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 19 | $350 |
| E.R. Squibb & Sons, L.L.C. BMY | 22 | $347 |
| Novo Nordisk Inc NVO | 12 | $319 |
| Scpharmaceuticals Inc. SCPH | 16 | $197 |
| Merck Sharp & Dohme LLC MRK | 10 | $187 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $187 |
| Pfizer Inc. PFE | 13 | $183 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 23 | $165 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $156 |
| Azurity Pharmaceuticals, Inc. | 12 | $143 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.